French-Canadian Translation and Cultural Adaptation of the Clinical Opiate Withdrawal Scale: The COWS-FC

Abstract
The assessment of opioid withdrawal symptoms is common in both clinical and research settings. The Clinical Opiate Withdrawal Scale (COWS) is among the most frequently used instruments for the assessment of signs and symptoms associated with opioid withdrawal. The COWS is a validated, clinician-administered instrument initially developed and validated for English-speaking populations. To date, however, the COWS has yet to be linguistically and culturally adapted for French-Canadian populations.

Objective: The main objective of the present study was to develop a French-Canadian translation and adaptation of the COWS (i.e., the COWS-FC) for the assessment of opioid withdrawal symptoms in clinical and research settings.

Methods: The French-Canadian translation and cultural adaptation of the COWS was performed following guidelines for the translation and cross-cultural adaptation of self-report measures. The steps consisted of (1) initial translation from English to French, (2) synthesis of the translation, (3) back-translation from French to English, (4) expert committee meeting, (5) test of
the prefinal version among healthcare professionals and (6) review of final version by the expert committee. The expert committee considered four major areas where the French-Canadian version should achieve equivalence with the original English version of the COWS. These areas were (1) semantic equivalence; (2) idiomatic equivalence; (3) experiential equivalence and (4) conceptual equivalence.

**Results:** Rigorous steps based on the guidelines for the translation and cultural adaptation of assessment tools were followed, which led to a semantically equivalent version of the COWS. After a pretest among healthcare professionals, members from the expert committee agreed upon slight modifications to the French-Canadian version of the COWS to yield a final COWS-FC version.

**Conclusions:** A French-Canadian translation and adaptation of the COWS (i.e., the COWS-FC) was developed. The COWS-FC could be used for the assessment of opioid withdrawal symptoms in clinical and research settings.

**Introduction**

Opioids refer to a class of natural, synthetic or semi-synthetic drugs that bind to opioid receptors. Opioids are commonly used for medical reasons (e.g., pain relief), but they are also used illicitly for recreational reasons. Whether used for medical or recreational reasons, it is well recognized that the prolonged use of opioids may lead to physical dependence due to opioid-induced neurobiological adaptations in the central nervous system. Signs of physical dependence on opioids are typically manifested by opioid withdrawal symptoms following cessation of opioids, decreases in opioid blood levels or administration of an opioid antagonist. Opioid withdrawal may be experienced with varying intensity and may include signs and symptoms such as tremors, sweating, yawning, piloerection, lacrimation, rhinorrhea, nausea, achiness, restlessness and dysphoria. Opioid withdrawal symptoms are mainly observed among illicit opioid users presenting with opioid use disorder (OUD), but transient opioid withdrawal symptoms may also be experienced towards the end of dosing intervals among patients prescribed daily opioid therapy, or when patients undergo opioid dose reduction.

The assessment of opioid withdrawal symptoms is common in both clinical and research settings. In the clinical settings, the assessment of opioid withdrawal symptoms is routinely performed for diagnostic or treatment planning.
purposes3,7,24,25 as well as in the context of buprenorphine–
naloxone induction.26–30 It is also important to assess
opioid withdrawal symptoms because they lead to psycho-
logical distress and contribute to decreased quality of
life.18,31–34 In research settings, opioid withdrawal symptoms
are commonly assessed in studies testing the effectiveness of
pharmacological26,35,36 and non-pharmacological37–39 inter-
ventions for individuals with OUD.

A number of instruments have been developed and vali-
dated for the assessment of opioid withdrawal symptoms,
including the Opiate Withdrawal Scale (OWS)40, the
Objective Opiate Withdrawal Scale41, the Subjective
Opiate Withdrawal Scale42, the Short Opiate Withdrawal
Scale (SOWS-G43), the Subjective Opiate Withdrawal
Questionnaire (SOWQ44), the Adjective Rating Scale for
Withdrawal (ARSW45) and the Clinical Opiate Withdrawal
Scale (COWS46). To date, however, none of these instru-
ments have been linguistically or culturally adapted for
French-Canadian populations. Among these instruments,
the COWS is one of the most commonly used. The COWS
is a validated, clinician-administered instrument that can be
used to quantify the frequency and severity of eleven
common signs and symptoms associated with opioid with-
drawal. It was developed for American English-speaking
populations in the early 2000s by Wesson and Ling46 and
later validated by Tompkins and colleagues.7 Because of its
good psychometric properties, clinical utility and ease of
application, the COWS has become widely used for the
assessment of opioid withdrawal symptoms, both in clinical
and research settings.47–52

The main objective of the present study was to develop a
French-Canadian translation and adaptation of the COWS
(i.e., the COWS-FC) that can be used for the assessment of
opioid withdrawal symptoms in clinical and research set-
tings. As recommended,53 linguistic translations of instru-
ments also need to be culturally adapted to the target
population. Given that up to seven million of Canadians
report French as their first official spoken language,54 there
is a need to develop a culturally adapted version of the
COWS that could be used by French Canadians in the prov-
ince of Quebec as well as in other Canadian provinces and
territories.

Methods

Original Instrument: The COWS

The COWS was first published as a training manual for OUD
treatment with buprenorphine.46 It was developed by Wesson
and Ling in response to increased rates of opioid prescription
among pain patients, as well as a gain in popularity of sublin-
gual buprenorphine in the United States. It was designed as a
clinician-administered instrument that rates 11 common
opioid withdrawal signs and symptoms46 and took into con-
sideration that each sign and symptom may occur along a
spectrum, as reflected by the use of graded responses. The
COWS consists of 11 items, including 1 subjective
symptom item, 6 objective sign items and 4 items that
included subjective and objective components. The final
score is a sum of all items, with the following cut-off
points: 5–12 = mild; 13–24 = moderate; 25–36 = moderately
severe; more than 36 = severe withdrawal. The scale was val-
ified in a sample of 46 out-of-treatment opioid-dependent
volunteers.9 The initial validation revealed a good internal
consistency, with a Cronbach α of 0.78.9

The COWS was specifically selected by our expert com-
mittee among the various scales for linguistic and cultural
adaptation given its psychometric properties, its previous val-
idation as an instrument for the assessment of withdrawal
symptoms among various populations of opioid users,55–62 as
well as for its ease of administration by clinicians.

Procedures

The translation and cultural adaptation of the COWS was
performed following guidelines for the translation and cross-
cultural adaptation of self-report measures published by
Beaton and colleagues.53 All the translation and cultural
adaptation procedures are described below.

Step 1: Initial (French) translation. The first step of the transla-
tion process was the forward translation from the original lan-
guage (i.e., English) to the target language (i.e.,
French-Canadian) by two bilingual individuals from the
province of Quebec, speaking French-Canadian as their
native language. These two translators had the ability to
speak both languages with the facility of a native speaker.
The first translator was an individual working in the field
of pain and opioids (T1), and the second translator was a cer-
tified French linguist with no biomedical background and
without any a priori knowledge of the concepts being mea-
ured (T2). Each individual involved in the translation
process produced a Canadian French version of the COWS
and a detailed report summarizing the rationale for their
choices of words, as well as comments regarding potentially
challenging phrases and concepts.

Step 2: Synthesis of the translations. A synthesis of the two
translated versions (from T1 and T2) was made following
the independent translations of the COWS. The two indepen-
dent translators and the research coordinators met through a
video conference platform to examine the results of the
first step and to reconcile any discrepancies. At the end of
the meeting, the team agreed upon a common
French-Canadian version and provided a unified preliminary
version of the COWS.

Step 3: Back translation. The third step consisted of a back-
translation of the questionnaire (i.e., from French to
English) by bilingual translators from Canada, speaking
English as their native language. One of the back-translators (BT1) was an individual working in the field of pain and opioids, and the other back-translator (BT2) was a certified English linguist with no biomedical background and/or knowledge of the field. Both individuals were blinded to the original English version of the COWS. As in the first step, each individual involved in the back-translation process generated an individual back-translated version of the COWS accompanied by a detailed report of their rationale for the choice of words and comments regarding potentially challenging phrases or concepts.

Following the back translation, a synthesis meeting was held between the two individuals involved in the back-translation and the research coordinator to compare the two back-translated versions and to reconcile any discrepancies. At the end of the synthesis meeting, a global report was created, which included the original English version of the COWS, the two French-Canadian versions, and the reports of the forward translators, the unified T-12 version, the two English back translations, and the reports from the back translators.

**Step 4: Expert committee.** The fifth stage involved an expert committee composed of healthcare professionals (i.e., physicians, nurses and clinical psychologists), researchers working in the field of opioids and research coordinators. The global report of the preceding step (i.e., Step 3) was sent to all committee members before the meeting. A teleconference (using a web-based screen-sharing system) was then organized with the objective of generating a prefinal French-Canadian version of the COWS. As recommended by Beaton et al., the experts considered four major areas where the French-Canadian version should achieve equivalence with the original English version of the COWS. The areas are (1) semantic equivalence (i.e., the meaning of words); (2) idiomatic equivalence (i.e., the meaning of expressions or idioms); (3) experiential equivalence (i.e., the adaptation or replacement of items that are specific to the target culture); and (4) conceptual equivalence (i.e., the definition of concepts that are common to both cultures).

**Step 5: Test of the prefinal version.** For the fifth step, the prefinal French-Canadian version of the COWS was pretested in a sample of 28 healthcare professionals working in francophone university-affiliated hospitals in the province of Quebec (see Table 1). The healthcare professionals that were recruited for the pretest were clinician working in the area of chronic pain or substance use (anesthesiologists, nurses, psychiatrists, pharmacists, family physicians). The healthcare professionals also had to be aged 18 years old or above and speak French as their native language. All procedures related to the pretest were approved by the Ethics Review Board of the Centre hospitalier de l’Université de Montréal.

Between October 2019 and December 2019, the convenience sample of healthcare professionals was contacted through institutional emails and invited to participate in the pretesting step, which took place through a web-based questionnaire. After providing consent, healthcare professionals were asked to read all instructions and items from the prefinal French-Canadian version of the COWS. They were then asked to provide open-ended comments regarding the clarity of each item. After providing comments on the prefinal French-Canadian version of the COWS, participants (i.e., healthcare professionals) were asked to provide socio-demographic information (i.e., age, gender, ethnicity) as well as information about their occupation and years of experience working with opioid users. The pretest took approximately 15 minutes in total, and no financial compensation was offered.

**Step 6: Final version.** During the final step, members from the expert committee agreed upon slight modifications to the French-Canadian version of the COWS after reviewing the

### Table 1. Characteristics of the Health Care Professionals Participating in the Study (N = 28).

| Characteristic                        | %    |
|--------------------------------------|------|
| **Age (years)**                      |      |
| 18–34                                | 22   |
| 35–44                                | 41   |
| 45–54                                | 15   |
| 55–65                                | 22   |
| **Gender**                           |      |
| Women                                | 78   |
| Men                                  | 22   |
| **Ethnicity**                        |      |
| Caucasian (White)                    | 93   |
| Other                                | 7    |
| **Occupation**                       |      |
| Nurse clinician                      | 30   |
| Nurse technician                     | 18   |
| Nurse auxiliary                      | 4    |
| Pharmacist                           | 11   |
| General practitioner                 | 15   |
| Anaesthesiologist                    | 22   |
| **Years of experience in their occupation** |    |
| ≤5                                   | 11   |
| 6–10                                 | 19   |
| 11–15                                | 11   |
| 16–20                                | 26   |
| 21–25                                | 11   |
| 26–30                                | 7    |
| >30                                  | 15   |
| **Years of experience with opioid users** |    |
| ≤5                                   | 23   |
| 6–10                                 | 12   |
| 11–15                                | 30   |
| 16–20                                | 15   |
| 21–25                                | 4    |
| 26–30                                | 4    |
| >30                                  | 12   |
results obtained in the pretest (see Table 2). The final version of the COWS-FC is presented in Online Appendix 1.

Results
All the steps (i.e., Steps 1–6) involved in the French-Canadian translation and cultural adaptation of the COWS took place between June and November 2019. Descriptive statistics for the sample of healthcare professionals who participated in the pretest of the COWS-FC are presented in Table 1. The majority of participants were women (78%), aged between 35 and 44 years (41%), and Caucasians (93%). Among these participants, nursing (52%) and medicine (37%) were the most frequent healthcare disciplines, and close to 90% of participants reported having worked with opioid users for more than 5 years.

Table 2 presents an overview of the results from the pretest (i.e., Step 5) conducted among healthcare professionals. The minor adjustments that were made to yield the final French-Canadian version of the COWS (i.e., COWS-FC) are also described in Table 2. Results from the pretest indicated that the vast majority of items from the prefinal version of the COWS-FC were clear and well understood by participants (i.e., healthcare professionals). However, based on participants’ suggestions, minor adjustments to certain words or statements were made to enhance clarity. For instance, this occurred for item # 4 (adding the words “rougeurs” and “diaphorèse”), item # 10 (adding the words “assis en place”) and item # 22 (adding the word “piloérection”). The wording of item # 12 in the final version was also slightly modified to more accurately represent one of the response choices (i.e., by adding the word “anormalement”). For the “total score” section, three participants suggested adding the word “sevrage” to the scoring legend, which was done in the final version to enhance clarity.

Some participants (n = 2) suggested adding one response choice (i.e., “modérés”) to item # 16, but this suggestion was not retained because it would have altered the scoring system implemented in the original version of the COWS. Similarly, suggestions were made to add additional items (e.g., an item assessing sleep disturbance and an item assessing the date/time of last adjuvant medication intake), but these suggestions were not retained because these items were not included in the original version of the COWS and this would have altered the original scoring system.

Discussion
The main objective of the present study was to develop a French-Canadian translation and adaptation of the COWS (i.e., the COWS-FC) for the assessment of opioid withdrawal symptoms in clinical and research settings. A number of instruments have previously been developed and validated for the assessment of opioid withdrawal symptoms, but none have been culturally adapted for French-Canadian populations. Opioid withdrawal symptoms are frequently assessed both in clinical and research settings, and there was a need to develop a culturally adapted version of the COWS that could be used by French Canadians.

Because of its psychometric properties, ease of application and clinical utility, the COWS has become widely used for the assessment of opioid withdrawal symptoms among various populations of opioid users. Results from the pretest conducted among healthcare professionals with experience working with opioid users showed that the French-Canadian version of the COWS was generally well understood by participants, both in terms of general instructions and item wording. Given the very few adjustments that needed to be made following the pretest, it is unlikely that the clarity and understandability of items from the COWS-FC meaningfully varied as a function of healthcare professionals’ demographic or occupational characteristics. Finally, the pretest did not reveal any specific challenge that would need to be addressed. Overall, the pretest led only to minor modifications to the wording of certain items to enhance clarity, without any alterations to the meaning of items included in the original (i.e., English) version of the COWS. The comparability and absence of any meaningful differences between the original English and French-Canadian versions of the COWS is expected to be useful not only for clinical purposes but also to facilitate comparisons across studies involving the assessment of opioid withdrawal symptoms using the COWS.

Strengths and Limitations
Rigorous steps based on the guidelines for the translation and cultural adaptation of assessment tools were followed, which led to a semantically equivalent version of the COWS. However, future studies that will use the COWS-FC should report its psychometric properties and compare them with those from the original version. Second, data from the pretest were collected among healthcare professionals from various disciplines having worked with opioid users for several years, but the distinction between healthcare professionals’ experience working with medical or nonmedical users was not made. It is unlikely that this distinction would have impacted healthcare professionals’ understandability of the COWS-FC, but this needs to be considered when interpreting results from the pretest. Finally, there are limitations associated with the initial version of the COWS that need to be considered. For instance, although the COWS has been used in clinical and research settings among patients prescribed opioids, it was primarily developed and validated for illicit opioid users. Further studies are needed to test the psychometric properties of the COWS among patients using opioids for medical reasons.

Despite these limitations, this study led to a linguistically and culturally adapted version of the COWS that is expected to be useful for the assessment of opioid withdrawal
Table 2. Overview of Results from the Pretest and Subsequent Changes Made to Yield the COWS-FC.

| Items of the Original COWS Title | Original Text | Penultimate French-Canadian Version | Comments from Clinicians Participating in the Survey | COWS-FC |
|-----------------------------------|--------------|-------------------------------------|------------------------------------------------------|---------|
| **Sweating** | - Sweating: over past 1/2 h not accounted for by room temperature or patient activity. 
- 0 no report of chills or flushing 
- 1 subjective report of chills or flushing 
- 2 flushed or observable moistness on face 
- 3 beads of sweat on brow or face 
- 4 sweat streaming off face | - Sudation : évaluée depuis les 30 dernières minutes, sans prendre en compte la sudation causée par la température de la pièce ou l'activité du patient. 
- 0 aucun frisson ou rougissement 
- 1 se plaint de frissons ou de rougissement 
- 2 rougissement ou sudation évidente au visage 
- 3 sueurs qui perlent sur le visage 
- 4 sueurs abondantes qui coulent du visage | - Clear, simple or no comments (n = 20) 
- Suggested adding the English word “flushing” which is frequently used (n = 1) 
- Concerns about weather or health condition that could cause sudation (n = 2) 
- Suggested observing moist hands and arms (n = 1) 
- Suggested using the word “rougeurs” instead of “rougissement” (n = 1) 
- Suggest some minor rewording of the sentence that did not change the meaning (n = 3) 
- Suggested adding the word “diaphorèse” (n = 1) | - Évaluation en vous basant sur les symptômes spécifiques au sevrage des opioïdes. Par exemple, si la fréquence cardiaque augmente parce que le patient est allé courir juste avant l'évaluation, vous ne devez pas tenir compte de l'augmentation de la fréquence cardiaque dans le score. 1. Fréquence cardiaque au repos : ________/min mesurée après plus d'une minute assis ou couché 0. pouls 80 ou moins 1. pouls entre 81 et 100 2. pouls entre 101 et 120 4. pouls à plus de 120 |
| **Resting pulse rate** | - Resting pulse rate (______ beats/min): 
  - Measured after patient is sitting or lying for one minute. 
  - 0 pulse rate 80 or below 
  - 1 pulse rate 81–100 
  - 2 pulse rate 101–120 
  - 4 pulse rate greater than 120 | - Fréquence cardiaque au repos : mesurée après une minute assis ou couché ________/min. 
  - 0 pouls à 80 ou moins 
  - 1 pouls entre 81–100 
  - 2 pouls entre 101–120 
  - 4 pouls à plus de 120 | - Clear, simple or no comments (n = 21) 
- Could be pertinent to indicate the resting pulse rate after 2–10 min sitting down (n = 3) 
- Pulse rate is usually measured over 15 s (n = 1) 
- Suggested indicating the numbers are “points” (n = 1) 
- Suggested rewording “Notez la fréquence cardiaque au repos” (n = 1) 
- Certain medications can have an impact on the pulse rate (n = 1) 
- Adding « pouls » at each answer is redundant (n = 1) | - N/A |
| Restlessness | Restlessness Observation during assessment |
|--------------|---------------------------------------------|
| 0 able to sit still | 1 reports difficulty sitting still, but is able to do so |
| 1 frequent shifting or extraneous movements of legs/arms | 3 change fréquemment de position ou mouvements involontaires des jambes/bras |
| 5 unable to sit still for more than a few seconds | 5 incapable de rester assis pendant plus de quelques secondes |

| Observation | Restlessness |
|-------------|--------------|
| 0 | 0 able to sit still |
| 1 | 3 change fréquemment de position ou mouvements involontaires des jambes/bras |
| 5 | 5 incapable de rester assis pendant plus de quelques secondes |

| Pupil size | Pupil size |
|------------|------------|
| 0 | 0 pupils pinnéd or normal size for room light |
| 1 | 1 pupils possibly larger than normal for room light |
| 2 | 2 pupils moderately dilated |
| 5 | 5 pupils so dilated that only the rim of the iris is visible |

| Tailles des pupilles | Tailles des pupilles |
|----------------------|----------------------|
| 0 | 0 grosseur normale à la lumière ambiante |
| 1 | 1 possiblement plus grandes que la normale compte tenu de la lumière ambiante |
| 2 | 2 dilatation modérée |
| 5 | 5 dilatation sévère (l’iris n’est presque plus visible) |

| Bone or joint aches | Bone or joint aches if patient was having pain previously, only the additional component attributed to opiates withdrawal is scored | Bone or joint aches |
|---------------------|---------------------------------------------------------------|---------------------|
| 0 | 0 not present |
| 1 | 1 mild diffuse discomfort |
| 2 | 2 patient reports severe diffuse aching of joints/muscles |
| 4 | 4 patient is rubbing joints or muscles and is unable to sit still because of discomfort |

| Douleur osseuse ou articulaire | Si le patient présentait de la douleur avant l’arrêt des opioïdes, ne tenir compte que des douleurs liées au sevrage |
|----------------------|---------------------------------------------------------------|
| 0 | 0 absent |
| 1 | 1 inconfort diffuse |
| 2 | 2 se plaint de douleur diffuse sévère des muscles/articulations |
| 4 | 4 patient se frotte les articulations/muscles et est incapable de rester tranquille à cause de la douleur |

| Douleur osseuse ou articulaire | Si le patient présentait de la douleur avant l’arrêt des opioïdes, ne tenir compte que des douleurs liées au sevrage |
|----------------------|---------------------------------------------------------------|
| 0 | 0 absent |
| 1 | 1 inconfort diffuse |
| 2 | 2 se plaint de douleur diffuse sévère des muscles/articulations |
| 4 | 4 patient se frotte les articulations/muscles et est incapable de rester tranquille à cause de la douleur |

| Runny nose or tearing | Runny nose or tearing Not accounted for by cold symptoms or allergies |
|----------------------|---------------------------------------------------------------|
| 0 | 0 not present |
| 1 | 1 nasal stuffiness or unusually moist eyes |
| 2 | 2 nose running or tearing |
| 4 | 4 nose constantly running or tears streaming down cheeks |

| Rhinorrhée ou larmoiement | Rhinorrhée ou larmoiement : non causé par un rhume ou des allergies |
|--------------------------|---------------------------------------------------------------|
| 0 | 0 absent |
| 1 | 1 congestion nasale, yeux humides |
| 2 | 2 rhinorrhée ou larmoiement |
| 4 | 4 rhinorrhée constante ou larmes qui coulent sur les joues |

| Rhinorrhée ou larmoiement | Rhinorrhée ou larmoiement : non causé par un rhume ou des allergies |
|--------------------------|---------------------------------------------------------------|
| 0 | 0 absent |
| 1 | 1 congestion nasale ou yeux anormalement humides |
| 2 | 2 rhinorrhée ou larmoiement |
| 4 | 4 rhinorrhée constante ou larmes qui coulent sur les joues |

| GI Upset | GI Upset: over last 1/2 h |
|----------|--------------------------|
| 0 | 0 no Gl symptoms |

| Inconfort gastro-intestinal | Inconfort gastro-intestinal depuis les 30 dernières |
|---------------------------|---------------------------------------------------|

| Clear, simple or no comments | Clear, simple or no comments |
|-------------------------------|-------------------------------|
| (n = 25) | In the hospital, some patients may be in other positions than sitting down (n = 1) Asked for clarifications about the word “agité” (n = 1) Suggested minor rewording “observez l’agitation” (n = 1) |

3. Agitation : observée durant l’évaluation 0. capable de rester assis 1. déclare avoir de la difficulté à rester assis, mais est capable de le faire 3. change fréquemment de position ou mouvements involontaires des jambes/bras 5. incapable de rester assis pendant plus de quelques secondes

4. Tailles des pupilles 0. grosseur normale à la lumière ambiante 1. possiblement plus grandes que la normale compte tenu de la lumière ambiante 2. dilatation modérée 5. dilatation sévère ou importante/maximale (l’iris n’est presque plus visible)

5. Douleur osseuse ou articulaire. Si le patient présentait de la douleur avant l’arrêt des opioïdes, ne tenir compte que des douleurs liées au sevrage 0. absente 1. inconfort diffus 2. se plaint de douleur diffuse sévère des muscles/articulations 4. patient se frotte les articulations/muscles et est incapable de rester tranquille/assis ou en place à cause de la douleur

6. Rhinorrhée ou larmoiement : non causé par un rhume ou les allergies 0. absent 1. congestion nasale ou yeux anormalement humides 2. rhinorrhée ou larmoiement

7. Inconfort gastro-intestinal : depuis les 30 dernières (continued)
### Table 2. Continued.

| Tremor | Tremblissements : observés avec les bras étendus, doigts écartés |
|--------|---------------------------------------------------------------|
| 0 no tremor | 0 aucun tremblement |
| 1 tremor can be felt, but not observed | 1 tremblements sont ressentis, mais non visibles |
| 2 slight tremor observable | 2 tremblements légers |
| 4 gross tremor or muscle twitching | 4 tremblements sévères ou spasmes musculaires |

| Anxiété ou irritabilité | Anxiété ou irritabilité |
|-------------------------|-------------------------|
| 0 none | 0 aucune anxiété ou irritabilité |
| 1 patient reports increasing irritability or anxiousness | 1 se plaint d’anxiété ou d’irritabilité |
| 2 patient obviously irritable or anxious | 2 anxiété ou irritabilité objetivable |
| 4 patient so irritable or anxious that participation in the assessment is difficult | 4 patient si anxieux ou irritable que sa participation à l’évaluation est difficile |

| Gooseflesh skin | Chair de poule |
|----------------|----------------|
| 0 skin is smooth | 0 peau lisse |
| 3 piloerrection of skin can be felt or hairs standing up on arms | 3 piloérrection est ressentie, on voit les poils des bras dressés |
| 5 prominent piloerrection | 5 piloërorection importante |

| Total score | The total score is the sum of all 11 items. |
|-------------|--------------------------------------------|
| Total score: | Score total: ________ |

---

**Tremor**

- **Tremor: observation of outstretched hands**
- **Tremblements : observés avec les bras étendus, doigts écartés**
- **Clear, simple or no comments**
  - **(n = 17)**
  - **Suggested adding a « modérés » category between “légers” and “sévères” (n = 2)**
  - **Suggested changing “étendus” for “tendus” (n = 2)**
  - **Suggested removing “observés avec les bras” (n = 1)**

**Yawning**

- **Yawning: observation during assessment**
- **Bâillements : observés durant l’évaluation**
- **Clear, simple or no comments**
  - **(n = 27)**
  - **Suggested replacing “observés” by “évaluation” (n = 1)**

**Anxiety or Irritability**

- **Anxiété ou irritabilité**
- **Clear, simple or no comments**
  - **(n = 22)**
  - **Suggested changing “objectivable” by “évidente” (n = 1)**
  - **Option 4 is not clear and should be reworded (n = 3)**

**Gooseflesh skin**

- **Chair de poule**
- **Clear, simple or no comments**
  - **(n = 26)**
  - **Suggested adding “piloëroction” to the title, since “chair de poule” is not a medical term (n = 1)**

**Total score**

- **The total score is the sum of all 11 items.**
- **Total score: ________**

---

**Tremblements : observés**

- **0. absent**
- **1. tremblements sont ressentis, mais non visibles**
- **2. tremblements légers**
- **4. tremblements sévères ou spasmes musculaires**

**Bâillements : observés**

- **0. aucun bâillement**
- **1. 1–2 bâillements durant l’évaluation**
- **2. 3 bâillements ou plus durant l’évaluation**
- **4. plusieurs bâillements/minute**

**Anxiété ou irritabilité**

- **0. aucune anxiété ou irritabilité**
- **1. se plaint d’anxiété ou d’irritabilité**
- **2. anxiété ou irritabilité objectivable**
- **4. patient si anxieux ou irritable que sa participation à l’évaluation est difficile**

**Chair de poule**

- **0 peau lisse**
- **3 piloérrection est ressentie, on voit les poils des bras dressés**
- **5 piloëroction importante**

**Score total : ________**

(Le score total est la somme de tous les items)
symptoms by French-Canadian populations. The linguistic and cultural adaptation conducted in the present study has broad applicability given that the COWS-FC is frequently used in both clinical and research settings. Clinicians and researchers working in francophone settings across Canada should now consider using the COWS-FC for the assessment of opioid withdrawal symptoms.

Authors’ Note
Members of the Quebec Pain Research Network Strategic Initiative on Opioids are (in alphabetical order): Archambault Léonie, Beaudet Nicolas, Beaudry Hélène, Bérubé Mélanie, Boulanger Aline, Bruneau Julie, Choinière Manon, Gauthier Lynn, Gélinas Céline, Gendron Louis, Guénette Line, Lacasse Anaïs, Lavigne Gilles, Lussier David, Martel Marc O., Pagé M. Gabrielle, Perreault Michel, Pinard Anne Marie, and Tousignant-Laflamme Yannick.

Acknowledgements
The authors would like to thank members from the Addictions Unit of the Centre hospitalier de l’Université de Montréal (CHUM), who provided input on our work and facilitated the translation and cultural adaptation process of the COWS. The authors also thank healthcare professionals who took the time to participate in this study.

Table 2. Continued.

| Score: | Le score total est la somme de tous les 11 items |
|--------|--------------------------------------------------|
| 5–12 = mild; 13–24 = moderate; 25–36 = moderately severe; more than 36 = severe withdrawal | Could indicate “severage” at each level (n = 3) |
| Score : 5–12 = léger; 13–24 = modéré; 25–36 = modérément sévère; plus de 36 = sevrage sévère. | Suggested rewording using “Interprétation: Severage d’intensité …” (n = 1) |
| The score 0–5 is not present (n = 1) | The score 0–5 is not present (n = 1) |
| Could be useful to add an item for sleepiness, depending on where the patient is seen (n = 1) | Could be useful to add an item for sleepiness, depending on where the patient is seen (n = 1) |
| Asked clarification about the consideration of resting pulse rate if a patient exercised before the assessment (n = 1) | Asked clarification about the consideration of resting pulse rate if a patient exercised before the assessment (n = 1) |
| Reword “somme de tous les items” (n = 1) | Reword “somme de tous les items” (n = 1) |
| Suggestion to improve the visual presentation (n = 1) | Suggestion to improve the visual presentation (n = 1) |
| Suggested adding a field for date & time of the assessment as well as a section to indicate time of last adjuvant medication intake (n = 1) | Suggested adding a field for date & time of the assessment as well as a section to indicate time of last adjuvant medication intake (n = 1) |

COWS: Clinical Opiate Withdrawal Scale.

Declaration of Conflicting Interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the Quebec Pain Research Network (Opioid Strategic Initiative), a network funded by the Fonds de recherche du Québec-Santé (FRQ-S).

ORCID iDs
Marc O. Martel https://orcid.org/0000-0002-8143-4622
Yannick Tousignant-Laflamme https://orcid.org/0000-0002-1133-8707

Supplemental Material
Supplemental material for this article is available online.

References
1. Kosten TR, George TP. The neurobiology of opioid dependence: implications for treatment. Sci Pract Perspect. 2002;1(1):13–20.
2. Srivastava AB, Mariani JJ, Levin FR. New directions in the treatment of opioid withdrawal. Lancet. 2020;395(10241):1938–1948.
3. Kosten TR, Baxter LE. Review article: effective management of opioid withdrawal symptoms: a gateway to opioid dependence treatment. Am J Addict. 2019;28(2):55–62.

4. Kreek MJ, Reed B, Butelman ER. Current status of opioid addiction treatment and related preclinical research. Sci Adv. 2019;5(10):eaax9140.

5. Nestler EJ. Historical review: molecular and cellular mechanisms of opiate and cocaine addiction. Trends Pharmacol Sci. 2004;25(4):210–218.

6. Heit HA. The truth about pain management: the difference between a pain patient and an addicted patient. Eur J Pain 2001;5(Suppl A):27–29.

7. Fareed A, Stout S, Casarella J, et al. Illicit opioid intoxication: diagnosis and treatment. Subst Abuse. 2011;5:17–25.

8. Sigmon SC, Bisaga A, Nunes EV, et al. Opioid detoxification and naltrexone induction strategies: recommendations for clinical practice. Am J Drug Alcohol Abuse. 2012;38(3):187–199.

9. Tompkins DA, Bigelow GE, Harrison JA, et al. Concurrent validation of the Clinical Opiate Withdrawal Scale (COWS) and single-item indices against the Clinical Institute Narcotic Assessment (CINA) opioid withdrawal instrument. Drug Alcohol Depend. 2009;105(1–2):154–159.

10. Ling W. A perspective on opioid pharmacotherapy: where we are and how we got here. J Neuroimmune Pharmacol. 2016;11(3):394–400.

11. Fiellin DA, Friedland GH, Gourevitch MN. Opiate dependence: rationale for efficacy and efficacy of new and new treatments. Clin Infect Dis 2006;43(Suppl 4):S173–S177.

12. Juurlink DN. Rethinking “doing well” on chronic opioid therapy. CMAJ. 2017;189(39):E1222–E123.

13. Murphy L, Babaei-Rad R, Buna D, et al. Guidance on opioid tapering in the context of chronic pain: evidence, practical advice and frequently asked questions. Can Pharm J (Ott). 2018;151(2):114–120.

14. Huhn AS, Tompkins DA, Campbell CM, et al. Individuals with chronic pain who misuse prescription opioids report sex-based differences in pain and opioid withdrawal. Pain Med. 2019;20(10):1942–1947.

15. Kahan M, Srivastava A, Wilson L, et al. Misuse of and dependence on opioids: study of chronic pain patients. Can Fam Physician. 2006;52(9):1081–1087.

16. Weiss RD, Potter JS, Griffin ML, et al. Reasons for opioid use among patients with dependence on prescription opioids: the role of chronic pain. J Subst Abuse Treat. 2014;47(2):140–145.

17. Coloma-Carmona A, Carballo JL, Rodriguez-Marin J, et al. Withdrawal symptoms predict prescription opioid dependence in chronic pain patients. Drug Alcohol Depend. 2019;195:27–32.

18. Bruneau A, Frimerman L, Verner M, et al. Day-to-day opioid withdrawal symptoms, psychological distress, and opioid craving in patients with chronic pain prescribed opioid therapy. Drug Alcohol Depend. 2021;225:108787.

19. Weinrib AZ, Burns LC, Mu A, et al. A case report on the treatment of complex chronic pain and opioid dependence by a multidisciplinary transitional pain service using the ACT Matrix and buprenorphine/naloxone. J Pain Res. 2017;10:747–755.

20. Daitch D, Daitch J, Novinson D, et al. Conversion from high-dose full-opioid agonists to sublingual buprenorphine reduces pain scores and improves quality of life for chronic pain patients. Pain Med. 2014;15(12):2087–2094.

21. Naylor MR, Naud S, Keefe FJ, et al. Therapeutic interactive voice response (TIVR) to reduce analgesic medication use for chronic pain management. J Pain. 2010;11(12):1410–1419.

22. Ralphe JA, de CWAC, Richardson PH, et al. Opiate reduction in chronic pain patients: a comparison of patient-controlled reduction and staff controlled cocktail methods. Pain 1994;56(3):279–288.

23. Sullivan MD, Turner JA, DiLodovico C, et al. Prescription opioid taper support for outpatients with chronic pain: a randomized controlled trial. J Pain. 2017;18(3):308–318.

24. Bruneau J, Ahamad K, Goyer ME, et al. Management of opioid use disorders: a national clinical practice guideline. CMAJ. 2018;190(9):E247–E357.

25. Becker WC, Merlin JS, Manhapa A, et al. Management of patients with issues related to opioid safety, efficacy and/or misuse: a case series from an integrated, interdisciplinary clinic. Addict Sci Clin Pract. 2016;11(1):3.

26. Weiss RD, Potter JS, Provost SE, et al. A multi-site, two-phase, Prescription Opioid Addiction Treatment Study (POATS): rationale, design, and methodology. Contemp Clin Trials. 2010;31(2):189–199.

27. Srivastava A, Kahan M, Nader M. Primary care management of opioid use disorders: abstinence, methadone, or buprenorphine-naloxone? Can Fam Physician. 2017;63(3):200–205.

28. Srivastava A, Kahan M, Leece P, et al. Buprenorphine unobserved “home” induction: a survey of Ontario’s addiction physicians. Addict Sci Clin Pract. 2019;14(1):18.

29. Srivastava A, Kahan M, Njoroge I, et al. Buprenorphine in the emergency department: randomized clinical controlled trial of clonidine versus buprenorphine for the treatment of opioid withdrawal. Can Fam Physician. 2019;65(5):e214–e220.

30. Wesson DR, Smith DE. Buprenorphine in the treatment of opiate dependence. J Psychoactive Drugs. 2010;42(2):161–175.

31. Oji-Mmuo CN, Speer RR, Gardner FC, et al. Prenatal opioid exposure heightens sympathetic arousal and facial expressions of pain/distress in term neonates at 24–48 hours post birth. J Matern Fetal Neonatal Med. 2019;33(23):3879–3886.

32. Krabbe PF, Koning JP, Heinen N, et al. Rapid detoxification from opioid dependence under general anaesthesia versus standard methadone tapering: abstinence rates and withdrawal distress experiences. Addict Biol. 2003;8(3):351–358.

33. Koob GF. Neurobiology of opioid addiction: opponent process, hyperkatifeia, and negative reinforcement. Biol Psychiatry. 2020;87(1):44–53.

34. Heslin KC, Stein JA, Heinzelerling KG, et al. Clinical correlates of health-related quality of life among opioid-dependent patients. Qual Life Res. 2011;20(8):1205–1213.

35. Gowing L, Ali R, White JM, et al. Buprenorphine for managing opioid withdrawal. Cochrane Database Syst Rev. 2017;2(2):CD002025.

36. Gowing L, Farrell MF, Ali R, et al. Alpha2-adrenergic agonists for the management of opioid withdrawal. Cochrane Database
37. Amato L, Minozzi S, Davoli M, et al. Psychosocial and pharmacological treatments versus pharmacological treatments for opioid detoxification. Cochrane Database Syst Rev. 2011;10:CD005031. https://www.cochrane.org/CD005031/ADDCITN_psychosocial-and-pharmacological-treatments-versus-pharmacological-treatments-for-opioid-detoxification.

38. Amato L, Minozzi S, Davoli M, et al. Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone for treatment of opioid dependence. Cochrane Database Syst Rev. 2011;10:CD004147. https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004147.pub4/full.

39. Weiss RD, Potter JS, Fiellin DA, et al. Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial. Arch Gen Psychiatry. 2011;68(12):1238–1246.

40. Bradley BP, Gossop M, Phillips GT, et al. The development of an opiate withdrawal scale (OWS). Br J Addict. 1987;82(10):1139–1142.

41. Drummond DC, Turkington D. Naltrexone and clonidine in heroin withdrawal treatment. Br J Psychiatry. 1989;154:571–572.

42. Handelsman L, Cochrane KJ, Aronson MJ, et al. Two new rating scales for opiate withdrawal. Am J Drug Alcohol Abuse. 1987;13(3):293–308.

43. Gossop M. The development of a Short Opiate Withdrawal Scale (SOWS). Addict Behav. 1990;15(5):487–490.

44. Loimer N, Linzmayer L, Grünberger J. Comparison between observer assessment and self rating of withdrawal distress during opiate detoxification. Drug Alcohol Depend. 1991;28(3):265–268.

45. Bickel WK, Stitzer ML, Bigelow GE, et al. A clinical trial of buprenorphine: comparison with methadone in the detoxification of heroin addicts. Clin Pharmacol Ther. 1988;43(1):72–78.

46. Wesson DR, Ling W. The Clinical Opiate Withdrawal Scale (COWS). J Psychoactive Drugs. 2003;35(2):253–259.

47. Setnik B, Pixton GC, Webster LR. Safety profile of extended-release morphine sulfate with sequestered naltrexone hydrochloride in older patients: pooled analysis of three clinical trials. Curr Med Res Opin. 2016;32(3):563–572.

48. Cunningham JL, Evans MM, King SM, et al. Opioid tapering in fibromyalgia patients: experience from an interdisciplinary pain rehabilitation program. Pain Med. 2016;17(9):1676–1685.

49. Setnik B, Roland CL, Goli V, et al. A clinical trial to determine if corelease of morphine and naltrexone from crushed extended-release capsules induces withdrawal in opioid-dependent patients: a descriptive analysis of six patients. J Opioid Manag. 2013;9(2):139–150.

50. Nielsen S, Hillhouse M, Weiss RD, et al. The relationship between primary prescription opioid and buprenorphine-naloxone induction outcomes in a prescription opioid dependent sample. Am J Addict. 2014;23(4):343–348.

51. Tompkins DA, Smith MT, Mintzer MZ, et al. A double blind, within subject comparison of spontaneous opioid withdrawal from buprenorphine versus morphine. J Pharmacol Exp Ther. 2014;348(2):217–226.

52. Webster LR, Smith MD, Unal C, et al. Low-dose naloxone provides an abuse-deterrent effect to buprenorphine. J Pain Res. 2015;8:791–798.

53. Beaton DE, Bombardier C, Guillemin F, et al. Guidelines for the process of cross-cultural adaptation of self-report measures. Spine (Phila Pa 1976). 2000;25(24):3186–3191.

54. Statistics Canada. Census in brief: French and the francophonie in Canada. Ottawa: Statistics Canada; 2011.

55. Rosenthal RN, Ling W, Casadonte P, et al. Buprenorphine implants for treatment of opioid dependence: randomized comparison to placebo and sublingual buprenorphine/naloxone. Addiction. 2013;108(12):2141–2149.

56. Northrup TF, Stotts AL, Green C, et al. Opioid withdrawal, craving, and use during and after outpatient buprenorphine stabilization and taper: a discrete survival and growth mixture model. Addict Behav. 2015;41:20–28.

57. Stein MD, Herman DS, Moitra E, et al. A preliminary randomized controlled trial of a distress tolerance treatment for opioid dependent persons initiating buprenorphine. Drug Alcohol Depend. 2015;147:243–250.

58. Fishman M, Tirado C, Alam D, et al. Safety and efficacy of lofexidine for medically managed opioid withdrawal: a randomized controlled clinical trial. J Addict Med. 2019;13(3):169–176.

59. Markman J, Gudin J, Rauck R, et al. SUMMIT-07: a randomized trial of NKTR-181, a new molecular entity, full mu-opioid receptor agonist for chronic low-back pain. Pain. 2019;160(6):1374–1382.

60. Neumann AM, Blondell RD, Hoopsick RA, et al. Randomized clinical trial comparing buprenorphine/naloxone and methadone for the treatment of patients with failed back surgery syndrome and opioid addiction. J Addict Dis. 2020;38(1):33–41.

61. Henningfield JE, Gudin J, Rauck R, et al. Measuring opioid withdrawal in a phase 3 study of a new analgesic, NKTR-181 (oxycodegol), in patients with moderate to severe chronic low back pain. Pain Med. 2020;21(8):1553–1561.

62. Springborg AD, Jensen EK, Kreilgaard M, et al. High-dose naloxone: effects by late administration on pain and hyperalgesia following a human heat injury model. A randomized, double-blind, placebo-controlled, crossover trial with an enriched enrollment design. PLoS One. 2020;15(11):e0242169.

63. Webster L, Gruener D, Kirby T, et al. Evaluation of the tolerability of switching patients on chronic full μ-opioid agonist therapy to buccal buprenorphine. Pain Med. 2016;17(5):899–907.

64. Katz N, Rauck R, Ahdieh H, et al. A 12-week, randomized, placebo-controlled trial assessing the safety and efficacy of oxymorphone extended release for opioid-naive patients with chronic low back pain. Curr Med Res Opin. 2007;23(1):117–128.

65. Hooten WM, Warner DO. Varenicline for opioid withdrawal in patients with chronic pain: a randomized, single-blinded, placebo controlled pilot trial. Addict Behav. 2015;42:69–72.